Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Stefan Korsten"'
Autor:
Dietrich W. Beelen, Peter Staib, Gero Massenkeil, Heidrun Hindahl, Andreas Faldum, Karsten Spiekermann, Stefan K. Bohlander, Anja Baumgartner, Christian Buske, Michael Unterhalt, Marion Subklewe, Dennis Görlich, Michael Fiegl, Gerald Meckenstock, Cristina Sauerland, Xaver Schiel, Guido Trenn, E. Roemer, Harald Biersack, Dirk Medgenberg, Birgit Braess, Raphael Koch, Bettina Zinngrebe, Jan Braess, Rainer Schwerdtfeger, Maike de Wit, Hans Walter Lindemann, Karl-Anton Kreuzer, Eva Lengfelder, Michael Uppenkamp, Dirk Behringer, Wolfgang Hiddemann, Ullrich Graeven, Ernst Spaeth-Schwalbe, Tobias Gaska, Bernhard Wörmann, Michael G. Kiehl, Stephanie Schneider, Stefan Korsten, Wolf-Dieter Ludwig, Susanne Amler, Rudolf Peceny, Martin Lablans, Yon-Dschun Ko, Annika Dufour
Publikováno v:
Leukemia
Dose-dense induction with the S-HAM regimen was compared to standard double induction therapy in adult patients with newly diagnosed acute myeloid leukemia. Patients were centrally randomized (1:1) between S-HAM (2nd chemotherapy cycle starting on da
Autor:
Michael Boedler, Stefan Korsten
Publikováno v:
DMW - Deutsche Medizinische Wochenschrift. 123:597-598
Autor:
Dirk Medgenberg, Anja Baumgartner, Guido Trenn, Ernst Spaeth-Schwalbe, Gerald Meckenstock, Stefan Korsten, Michael Uppenkamp, Jan Braess, Rudolf Peceny, Birgit Braess, Yon-Dschun Ko, Harald Biersack, Dietrich W. Beelen, Xaver Schiel, E. Roemer, Heidrun Hindahl, Annika Dufour, Maike de Wit, Peter Staib, Karsten Spiekermann, Marion Subklewe, Rainer Schwerdtfeger, Wolf-Dieter Ludwig, Cristina Sauerland, Wolfgang Hiddemann, Gero Massenkeil, Stefan K. Bohlander, Christian Buske, Susanne Amler, Michael G. Kiehl, Ullrich Graeven, Michael Fiegl, Michael Unterhalt, Karl-Anton Kreuzer, Eva Lengfelder, Bettina Zinngrebe, Bernhard J. Woermann, Hans Walter Lindemann, Andreas Faldum, Dirk Behringer, Tobias Gaska, Stephanie Schneider
Publikováno v:
Blood. 122:619-619
Background For curative treatment of younger patients with acute myeloid leukemia (AML) double induction with two cycles of intensive cytarabine/ anthracycline based chemotherapy 21 days apart is the current standard of care. In the prospective rando